Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Analgesic and Antiemetic Regimen for Medical Abortion
NCT05819619Phase 1Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen and ondansetron in pain and nausea ((none)) (2 arms), sponsored by Hackensack Meridian Health. Primary endpoints: Patient Satisfaction at 2 weeks and Patient Satisfaction Based on Recommendation of Regimen at 2 weeks. Started Jul 2023; status: terminated.
02
Drugs
ibuprofenondansetron
03
Conditions
painnausea ((none))
Beyond the preview
Go deeper on NCT05819619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819619.